Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders

1. A food product effective for treating a patient suffering from a condition selected from the group consisting of metabolic syndrome, obesity, type 2 diabetes, pre-diabetes, hypertension, dyslipidemia, insulin resistance, endothelial dysfunction, pro-inflammatory state, and procoagulative state, said food product comprising:

(a) nutrients that decrease overactive CNS noradrenergic tone selected from the group consisting of pantethine, neuronal noradrenaline synthesis inhibitors, neuronal postsynaptic noradrenergic receptor blockers, neuronal presynaptic noradrenaline reuptake enhancers, neuronal presynaptic noradrenaline receptor stimulators, neuronal presynaptic noradrenaline release inhibitors, noradrenaline degradation enzyme stimulators, neuronal postsynaptic noradrenaline signal transduction inhibitors, and combinations thereof; and

(b) nutrients that increase dopaminergic tone selected from the group consisting of L-DOPA, neuronal dopamine synthesis stimulators, neuronal postsynaptic dopaminergic receptor stimulators, neuronal presynaptic dopamine reuptake inhibitors, neuronal presynaptic dopamine receptor blockers, neuronal presynaptic dopamine release enhancers, dopamine degradation enzyme inhibitors, neuronal postsynaptic dopamine signal transduction stimulators, and combinations thereof.

2. The food product of claim 1 , further comprising:

1) protein of about 25%±5% of total daily caloric intake;

2) monounsaturated fat of about 25%±5% of total daily caloric intake;

3) saturated fat of about 5%±5% of total daily caloric intake;

4) polyunsaturated fat of about 3%±5% of total daily caloric intake; and

5) complex carbohydrate of about 42%±7% of total daily caloric intake.

3. The food product of claim 1 , further comprising:

1) protein of about 24%±5% of total daily caloric intake;

2) monounsaturated fat of about 23%±5% of total daily caloric intake;

3) saturated fat of about 5%±5% of total daily caloric intake;

4) polyunsaturated fat of about 3%±5% of total daily caloric intake; and

5) complex carbohydrate of about 45%±7% of total daily caloric intake.

4. The food product of claim 2 , wherein said polyunsaturated fat further comprises omega-3 and omega-6 polyunsaturated fatty acids, present in a ratio of omega-3 to omega-6 polyunsaturated fatty acids of from between about 0.25:1 to about 2:1.

5. The food product of claim 1 , wherein said food product is selected from the group consisting of packaged foods, prepared meals, food bars, drinks, condiments, and combinations thereof.

6. The food product of claim 3 , wherein the nutrient that increases dopaminergic tone is L-DOPA, and said L-DOPA is present in an amount of between 20-400 mg.

7. The food product of claim 3 , wherein said polyunsaturated fat further comprises omega-3 and omega-6 polyunsaturated fatty acids, present in a ratio of omega-3 to omega-6 polyunsaturated fatty acids of from between about 0.25:1 to about 2:1.

8. The food product of claim 2 , wherein said food product provides between 75 and 85% of said patient's daily energy expenditure.

9. The food product of claim 3 , wherein said food product provides between 75 and 100% of said patient's daily energy expenditure.

10. The food product of claim 1 wherein the nutrient that increases dopaminergic tone is L-DOPA.

11. The food product of claim 10 wherein the nutrient that decreases overactive CNS noradrenergic tone is pantethine.

12. The food product of claim 1 wherein the nutrient that decreases overactive CNS noradrenergic tone is pantethine.